Similar articles for PMID: 17631558

Year	Number of Results
1983	2
1985	2
1986	1
1987	3
1988	1
1989	2
1990	2
1991	4
1993	1
1994	2
1995	4
1996	3
1997	1
1998	3
1999	2
2000	2
2001	6
2002	2
2003	6
2004	8
2005	5
2006	2
2007	9
2008	11
2009	10
2010	12
2011	8
2012	8
2013	16
2014	5
2015	16
2016	16
2017	16
2018	14
2019	13
2020	8
2021	12
2022	8
2024	0

1

The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions.

Mavi A, Cermik TF, Urhan M, Puskulcu H, Basu S, Yu JQ, Zhuang H, Czerniecki B, Alavi A. Mavi A, et al. J Nucl Med. 2007 Aug;48(8):1266-72. doi: 10.2967/jnumed.106.037440. Epub 2007 Jul 13. J Nucl Med. 2007. PMID: 17631558 Free article.

2

Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.

Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A. Basu S, et al. Cancer. 2008 Mar 1;112(5):995-1000. doi: 10.1002/cncr.23226. Cancer. 2008. PMID: 18098228 Free article. Clinical Trial.

3

Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18F-FDG.

Wang CL, MacDonald LR, Rogers JV, Aravkin A, Haseley DR, Beatty JD. Wang CL, et al. AJR Am J Roentgenol. 2011 Aug;197(2):W247-55. doi: 10.2214/AJR.11.6478. AJR Am J Roentgenol. 2011. PMID: 21785049

4

18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.

Osborne JR, Port E, Gonen M, Doane A, Yeung H, Gerald W, Cook JB, Larson S. Osborne JR, et al. J Nucl Med. 2010 Apr;51(4):543-50. doi: 10.2967/jnumed.108.060459. Epub 2010 Mar 17. J Nucl Med. 2010. PMID: 20237034 Free PMC article. Clinical Trial.

5

Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.

Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H. Ueda S, et al. Jpn J Clin Oncol. 2008 Apr;38(4):250-8. doi: 10.1093/jjco/hyn019. Jpn J Clin Oncol. 2008. PMID: 18407934

6

The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.

Cokmert S, Tanriverdi O, Karapolat I, Demir L, Bayoglu V, Can A, Akyol M, Yilmaz Y, Oktay Tarhan M. Cokmert S, et al. J BUON. 2016 Nov-Dec;21(6):1410-1418. J BUON. 2016. PMID: 28039701 Free article.

7

Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer.

Ahn SG, Lee JH, Lee HW, Jeon TJ, Ryu YH, Kim KM, Sohn J, Yun M, Lee SA, Jeong J, Kim SI. Ahn SG, et al. PLoS One. 2017 Apr 18;12(4):e0175048. doi: 10.1371/journal.pone.0175048. eCollection 2017. PLoS One. 2017. PMID: 28419166 Free PMC article.

8

Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.

Yoon HJ, Kang KW, Chun IK, Cho N, Im SA, Jeong S, Lee S, Jung KC, Lee YS, Jeong JM, Lee DS, Chung JK, Moon WK. Yoon HJ, et al. Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1534-43. doi: 10.1007/s00259-014-2744-4. Epub 2014 Mar 21. Eur J Nucl Med Mol Imaging. 2014. PMID: 24652232

9

18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.

García Vicente AM, Soriano Castrejón A, Relea Calatayud F, Muñoz Madero V, Molina Garrido MJ, León Martín AA, Cordero García JM, Pilkington Woll JP, Chacón López-Muñiz I, Palomar Muñoz A. García Vicente AM, et al. Rev Esp Med Nucl Imagen Mol. 2012 Nov-Dec;31(6):308-14. doi: 10.1016/j.remn.2011.12.001. Epub 2012 Mar 19. Rev Esp Med Nucl Imagen Mol. 2012. PMID: 23084013 Clinical Trial.

10

Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.

Groheux D, Hatt M, Hindié E, Giacchetti S, de Cremoux P, Lehmann-Che J, Martineau A, Marty M, Cuvier C, Cheze-Le Rest C, de Roquancourt A, Visvikis D, Espié M. Groheux D, et al. Cancer. 2013 Jun 1;119(11):1960-8. doi: 10.1002/cncr.28020. Epub 2013 Mar 15. Cancer. 2013. PMID: 23504954 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

219 results

Results by year